|
Aztreonam (trade names Azactam injection, Cayston inhalation) is a monobactam antibiotic used primarily to treat infections caused by gram-negative bacteria. It is a synthetic drug based on a simpler monobactam isolated from ''Chromobacterium violaceum''. It is resistant to some beta-lactamases, but is inactivated by extended-spectrum beta-lactamases. It was approved by the U.S. Food and Drug Administration (FDA) in 1986. == Medical uses == Aztreonam has strong activity against susceptible Gram-negative bacteria, including ''Pseudomonas aeruginosa''. It has no useful activity against Gram-positive bacteria or anaerobes. It is known to be effective against a wide range of bacteria including ''Citrobacter'', ''Enterobacter'', ''E. coli'', ''Haemophilus'', ''Klebsiella'', ''Proteus'', and ''Serratia'' species. The following represents MIC susceptibility data for a few medically significant microorganisms. * ''Staphylococcus aureus'' 8 - >128 μg/ml * ''Staphylococcus epidermidis'' 8 - 32 μg/ml * ''Streptococcus pyogenes'' 8 - ≥128 μg/ml 〔http://www.toku-e.com/Assets/MIC/Aztreonam.pdf〕 Synergism between aztreonam and arbekacin or tobramycin against ''P. aeruginosa'' has been suggested. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Aztreonam」の詳細全文を読む スポンサード リンク
|